Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Menzel

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Lancet (London, England)|August 9, 2005
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialRaimund Jakesz, Walter Jonat, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupMichael F X Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5Raimund Jakesz, Hubert Hausmaninger, Ernst Kubista, et al.
Proteomics|October 4, 2002
Evaluation of proteome reference maps for cross-species identification of proteins by peptide mass fingerprintingUlrike Mathesius, Nijat Imin, Hancai Chen, et al.
Breast Cancer Research and Treatment|December 26, 2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Brigitte Mlineritsch, Christoph Tausch, Christian Singer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2013
IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysisGerd Fastner, Felix Sedlmayer, Florian Merz, et al.
Annals of Surgery|April 5, 2003
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study GroupRaimund Jakesz, Hellmut Samonigg, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6Marianne Schmid, Raimund Jakesz, Hellmut Samonigg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14Günther G Steger, Arik Galid, Michael Gnant, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Lancet (London, England)|August 9, 2005
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialRaimund Jakesz, Walter Jonat, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupMichael F X Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5Raimund Jakesz, Hubert Hausmaninger, Ernst Kubista, et al.
Proteomics|October 4, 2002
Evaluation of proteome reference maps for cross-species identification of proteins by peptide mass fingerprintingUlrike Mathesius, Nijat Imin, Hancai Chen, et al.
Breast Cancer Research and Treatment|December 26, 2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Brigitte Mlineritsch, Christoph Tausch, Christian Singer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2013
IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysisGerd Fastner, Felix Sedlmayer, Florian Merz, et al.
Annals of Surgery|April 5, 2003
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study GroupRaimund Jakesz, Hellmut Samonigg, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6Marianne Schmid, Raimund Jakesz, Hellmut Samonigg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14Günther G Steger, Arik Galid, Michael Gnant, et al.
The Lancet. Oncology|June 7, 2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialMichael Gnant, Brigitte Mlineritsch, Herbert Stoeger, et al.
Pageof 6